SOLV — Solventum Corporation

Momentum is positive: Q2 2026 organic revenue grew 9.5%, adjusted EPS surged 50.9% YoY to $2.55, management raised full-year 2026 guidance, and the HIS separation announcement is seen as a catalyst to re-rate Solventum as a cleaner MedTech pure-play. The stock is 18.3% above its 200-day SMA as of 2026-08-27 and the analyst consensus is Buy, reflecting this improved market mood.

Reported quarterly revenue has been essentially flat for three years—roughly $2.0B–$2.16B per quarter from 2023 through 2025—so Q2 2026's $2.21B is the first clear breakout. But reported growth was only 2.2% YoY; the 9.5% organic number is the real signal. GAAP margins and EPS are badly distorted by one-off items: Q3 2025 net income of $1.27B and an anomalous Q4 2025 reported operating income of $1.68B that exceeds gross profit. The cleaner read is adjusted EPS, which jumped 50.9% in Q2 2026, though underlying GAAP operating margin was only about 8.2% as standalone public-company costs keep inflating SG&A. Net: this is a one-quarter inflection, not yet a multi-year trend.

Trailing GAAP P/E of 11.1x is misleading because TTM EPS is inflated by one-time gains. On FY2026 adjusted EPS guidance of $7.10–$7.20, SOLV trades at roughly 12.7x forward earnings—basically in line with its own 5-year average P/E of 12.54x. Price-to-sales of 1.89x is above the 5-year average of 1.62x, so the stock is not cheap. With debt-to-equity around 1.1x and a current ratio near 1.02x, valuation is fair, not bargain-priced.

At ~12.7x forward adjusted EPS, the market is paying a reasonable, not euphoric, multiple for an improving story. If the HIS separation succeeds and Solventum re-rates as a higher-margin MedTech pure-play, 14–15x forward EPS could put fair value around $100–$107. If organic growth fades or FCF stays lumpy, the multiple could compress toward 11x, implying mid-$70s to low-$80s. The near-high price means expectations are already rising; actual earnings delivery, not just guidance, will decide the next leg.

The technical setup is bullish but extended. As of 2026-08-27, RSI is 64.71—approaching overbought but not there yet. Price is 3.9% above the 20-day SMA, 10.8% above the 50-day SMA, and 18.3% above the 200-day SMA. The stock has been in a strong uptrend within its $62.38–$92.71 range, but chasing here carries pullback risk. A break above $92.71 would open new highs; a pullback toward the 50-day SMA near $82 would offer a better risk/reward entry.

• Interest-rate sensitivity: debt-to-equity ~1.1x and elevated post-spin leverage make deleveraging and earnings sensitive to rates.
• Defensive healthcare demand: resilient elective procedure volumes support MedSurg and Dental organic growth.
• Cost inflation: wage, supply-chain, and standalone public-company costs are pressuring SG&A, which rose ~20% YoY in Q2.
• FX translation: reported growth of 2.2% versus 9.5% organic highlights a meaningful currency/external headwind.
• Spin execution and healthcare regulatory/tax policy around the HIS separation.

• HIS separation execution: tax-free mechanics, timeline, and resulting capital structure.
• Q3 2026 earnings in early November 2026: confirmation of sustained >9% organic growth and improved FCF.
• Further adjusted EPS guidance raises if standalone cost pressures ease.
• FCF inflection and balance-sheet deleveraging beyond Q2 2026's $144M FCF print.

• Weak and volatile free cash flow: TTM FCF through Q2 2026 was roughly -$118M despite a positive Q2.
• Standalone cost inflation from the 3M separation could keep SG&A elevated for longer than expected.
• High leverage: long-term debt of $4.57B and D/E ~1.1x leaves little buffer if rates stay high.
• The HIS separation could be complex, taxable, or distracting, and organic growth could decelerate after the Q2 spike.
• Reported data contain serious one-off distortions, making underlying earnings quality harder to assess.

Solventum is executing better operationally—Q2 2026's 9.5% organic growth and 50.9% adjusted EPS growth are real, and the HIS separation is a credible value-unlock. But the fundamentals are not strong enough to justify chasing at the top of the range: FCF has been negative over the trailing year, leverage is meaningful, and GAAP numbers are clouded by one-offs. This is a solid hold/watch name, not a high-conviction buy at $90.93; wait for either a pullback or continued FCF/organic growth confirmation.

Calculated by applying a 13.5x forward P/E to FY2026 adjusted EPS guidance midpoint of $7.15 (13.5 × $7.15 = $96.53, rounded to $96.50). The multiple is a modest premium to Solventum's 5-year average of 12.54x, justified by 9.5% organic growth and the likely pure-play re-rating from the HIS separation, but capped by ~1.1x debt-to-equity and negative trailing free cash flow.